Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amiloride versus placebo for lithium-induced nephrogenic diabetes insipidus
ACTRN12610000428066Phase 4Completed
- Sponsor
- Health Research Council of New Zealand
- Start
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of amiloride in Arginine Vasopressin Resistance (AVP-R) (2 arms), sponsored by Health Research Council of New Zealand. Primary endpoints: Modification of urinary concentrating ability and Urine aquaporin 2 concentration. Started Feb 2007; status: completed.
02
Drugs
amiloride
03
Conditions
Arginine Vasopressin Resistance (AVP-R)
Beyond the preview
Go deeper on ACTRN12610000428066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000428066.